ProSense Cryoablation System to be showcased at healthcare conference

IceCure Medical LTD., developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, will participate in the Maxim Group LLC’s (“Maxim”) Healthcare Virtual Conference (the “Conference”), held from Tuesday, June 20th through Thursday, June 22nd.

The Company’s Chief Executive Officer, Eyal Shamir, will present on the unique advantages of the liquid nitrogen-based ProSense Cryoablation System (“ProSense”) and discuss the previously disclosed promising interim results from the Company’s ICE3 clinical trial for the indication of early-stage (Luminal A T1 invasive) low-risk breast cancer in patients who are at high risk to surgery (not suitable for surgical alternatives). In the largest study of its kind, 96.91% of patients were recurrence-free and 100% of patients and physicians reported satisfaction with the cosmetic results. No scarring or change to the shape or size of the breast resulted due to the procedure. The brief presentation, followed by a Q&A with Maxim’s research analyst, will take place on Wednesday, June 21st at 11:00 AM Eastern Time on Track 2.

ProSense serves the global tumor ablation market projected to reach $2.4 billion by 2028. An estimated 288,000 new cases of invasive breast cancer were diagnosed among U.S. women in 2022. ProSense has regulatory approvals in over 15 markets, a growing number of distribution agreements, and approximately 30 patents for its advanced liquid nitrogen cryoablation technology.

The Conference is being hosted by M-Vest, a division of Maxim, and investors should contact their sales representatives at Maxim Group to schedule a virtual meeting with IceCure Medical’s management team. PR Newswire